Compare Ascendis Pharma A/S (ASND) vs Snap Inc (SNAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Snap Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Snap Inc trades at $4.67 (market cap $7.87B). The key difference: Ascendis Pharma A/S is far larger — about 2.3× Snap Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.
| ASND | SNAP | |
|---|---|---|
Market Cap | $17.74B | $7.87B |
Sector | Health | Media |
52-Week High | $277.18 | $10.35 |
52-Week Low | $163.32 | $3.93 |
Enterprise Value | $18.11B | $9.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Snap Inc. (SNAP) trades at $4.68, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported revenue of $5.93 billion in 2025, with a net loss narrowing to -$460 million, showing improved profitability trends. Recent news highlights the launch of SPECS AR glasses priced at $2,195, which has drawn investor skepticism over pricing and demand.
The outlook remains cautious; while Snap has beaten EPS estimates in recent quarters and holds a consensus price target of $6.92, high debt levels and persistent net losses pose risks. Investor sentiment is mixed amid competitive pressures and regulatory scrutiny, requiring careful evaluation of growth initiatives against financial sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
